Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/353278/000117184317000780/f20f_020917.htm
March 2023
March 2023
March 2023
March 2023
March 2023
March 2023
March 2023
February 2023
February 2023
February 2023
Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/353278/000117184317000780/f20f_020917.htm
Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Novo Nordisk A S.
Novo Nordisk A S's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Novo Nordisk A S provided additional information to their SEC Filing as exhibits
Ticker: NVO
CIK: 353278
Form Type: 20-F Annual Report
Accession Number: 0001171843-17-000780
Submitted to the SEC: Thu Feb 09 2017 7:17:11 AM EST
Accepted by the SEC: Thu Feb 09 2017
Period: Saturday, December 31, 2016
Industry: Pharmaceutical Preparations